Aceragen

Aceragen is a biopharmaceutical company dedicated to developing innovative therapies for rare and ultra-rare diseases. The company is developing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other disorders associated with ceramide metabolism dysfunction.